CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer
Metrics: PDF 1695 views | HTML 2805 views | ?
Minh Nam Nguyen1,*, Tae Gyu Choi1,*, Dinh Truong Nguyen2, Jin-Hwan Kim1, Yong Hwa Jo1, Muhammad Shahid1, Salima Akter1, Saurav Nath Aryal1, Ji Youn Yoo1, Yong-Joo Ahn1, Kyoung Min Cho1, Ju-Seog Lee3, Wonchae Choe1, Insug Kang1, Joohun Ha1, Sung Soo Kim1
1Department of Biochemistry and Molecular Biology, Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Kyung Hee University, Seoul, Republic of Korea
2School of Biotechnology, Tan Tao University, Long An, Vietnam
3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
*These authors have contributed equally to this work
Sung Soo Kim, e-mail: [email protected]
Keywords: colorectal cancer, microarray analysis, gene expression profile, risk prediction
Received: June 26, 2015 Accepted: August 28, 2015 Published: September 11, 2015
Colorectal cancer (CRC) is the third leading cause of global cancer mortality. Recent studies have proposed several gene signatures to predict CRC prognosis, but none of those have proven reliable for predicting prognosis in clinical practice yet due to poor reproducibility and molecular heterogeneity. Here, we have established a prognostic signature of 113 probe sets (CRC-113) that include potential biomarkers and reflect the biological and clinical characteristics. Robustness and accuracy were significantly validated in external data sets from 19 centers in five countries. In multivariate analysis, CRC-113 gene signature showed a stronger prognostic value for survival and disease recurrence in CRC patients than current clinicopathological risk factors and molecular alterations. We also demonstrated that the CRC-113 gene signature reflected both genetic and epigenetic molecular heterogeneity in CRC patients. Furthermore, incorporation of the CRC-113 gene signature into a clinical context and molecular markers further refined the selection of the CRC patients who might benefit from postoperative chemotherapy. Conclusively, CRC-113 gene signature provides new possibilities for improving prognostic models and personalized therapeutic strategies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.